Inspira Technologies OXY B.H.N. Ltd. announced a partnership with Ennocure MedTech Ltd. At the core of Inspira's mission is a approach to oxygenate blood directly to replace life support mechanical ventilation. Inspira seeks to include bio-electronic technology as part of the INSPIRA ART and Company's IP portfolio, to prevent the growth of bacteria that often results in a bloodstream infection (sepsis) and has partnered with Ennocure for the development of such treatment. Once developed, Inspira plans to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce complications.
Inspira Technologies Oxy B.H.N. Ltd.
Equities
IINN
IL0011715781
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.87 USD | -1.06% | -1.58% | +76.42% |
1st Jan change | Capi. | |
---|---|---|
+76.42% | 32.68M | |
+2.80% | 3.48B | |
-11.37% | 156M | |
-14.72% | 81.85M | |
+30.43% | 59.71M |
- Stock Market
- Equities
- IINN Stock
- News Inspira Technologies Oxy B.H.N. Ltd.
- Inspira Collaborates with Ennocure for Development of Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients